FOXP3 and neoplasm: Four of five long-term survivor mice in the CT plus Foxp3-ASO, four of seven mice in the triple combination arm and one out of three mice in the CT plus anti-stab1 antibody treatment arm were alive at 380 days with no grossly visible tumour post-mortem.